-
Sol-Gel NASDAQ:SLGL Sol-Gel is a clinical-stage dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. Sol-Gel leverages its proprietary microencapsulation technology platform for the development of Twyneo, under investigation for the treatment of acne vulgaris, and Epsolay, under investigation for the treatment of inflammatory lesions of rosacea. The Company's pipeline also includes SGT-210 (erlotinib gel), under investigation for the treatment of palmoplantar keratoderma, and three pre-clinical assets - erlotinib, tapinarof and roflumilast - currently being tested for various pharmaceutical indications.
Location: Weizmann Science Park, Ness Ziona, 7403650, Israel | Website: www.sol-gel.com | Industry: Medicinal and Botanical Manufacturing | Sector: Manufacturing
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
-10.94M
Cash
30.47M
Avg Qtr Burn
-4.256M
Short % of Float
1.26%
Insider Ownership
65.17%
Institutional Own.
26.44%
Qtr Updated
06/30/24
Drug Pipeline
Powered by
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
EPSOLAY® (benzoyl peroxide) Cream Details Papulopustular Rosacea | Approved Update | |
Approved Quarterly sales | ||
SGT-610 (Patidegib) Details Gorlin Syndrome, Basal cell carcinoma | Phase 3 Data readout | |
SGT-210 (Erlotinib) Details Pachyonychia congenita, Skin disease/disorder | IND Submission |